Authors (including presenting author) :
Lam KY(1), Tsui PT(2), Ng V(1)
Affiliation :
(1)Pharmacy Department, Princess Margaret Hospital, (2)Department of Medicine and Geriatrics, Princess Margaret Hospital
Introduction :
Percutaneous coronary intervention (PCI) is one of the options for acute management of acute coronary syndrome (ACS). Followed by PCI, dual antiplatelet therapy (DAPT) comprising aspirin and a P2Y12 inhibitor is used to prevent recurrent atherothrombotic events. Superiority of ticagrelor over clopidogrel was established in the PLATO trial. No other studies had focused on the Chinese population, except the PHILO trial which mirrored the design of PLATO trial and targeted Asians.
Objectives :
To investigate the efficacy and safety of ticagrelor in comparison with clopidogrel in patients undergoing PCI at a local regional hospital in Hong Kong.
Methodology :
This was a single-centre, retrospective, observational study conducted in Princess Margaret Hospital (PMH). Chinese patients who were admitted to PMH and underwent PCI between 1st January 2013 and 31st December 2016 and received either ticagrelor or clopidogrel for at least 4 weeks together with aspirin (i.e. DAPT) following PCI were identified. Eligible patients were followed up for 12 months since the day when PCI was performed.
Result & Outcome :
439 patients were included in this study, among which 218 received ticagrelor and 221 received clopidogrel. Primary efficacy endpoint (composite of death from MI, stroke, or any causes) was reached by 1.4% in the ticagrelor arm versus 3.6% in the clopidogrel arm. Secondary efficacy endpoint (occurrence of non-fatal MI or stroke, probable or definite stent thrombosis) was reached by 2.8% and 1.4% in the ticagrelor arm and clopidogrel arm respectively. Major bleeding had occurred in 1.8% in the ticagrelor group and 2.3% in the clopidogrel group. Minor bleeding had occurred in 15.6% and 4.5% in the ticagrelor and clopidogrel groups respectively (p<0.001).
Co-location with:
